Lichen sclerosus explained

Lichen sclerosus
Field:Gynaecology
Synonyms:Balanitis xerotica obliterans, lichen sclerosus et atrophicus,[1] Lichen sclerosis et atrophicus,[2] lichen plan atrophique, lichen plan scléreux, Kartenblattförmige Sklerodermie, Weissflecken Dermatose, lichen albus, lichen planus sclerosus et atrophicus, dermatitis lichenoides chronica atrophicans, kraurosis vulvae[3]

Lichen sclerosus (LS) is a chronic, inflammatory skin disease of unknown cause which can affect any body part of any person but has a strong preference for the genitals (penis, vulva) and is also known as balanitis xerotica obliterans (BXO) when it affects the penis. Lichen sclerosus is not contagious. There is a well-documented increase of skin cancer risk in LS, potentially improvable with treatment. LS in adult age women is normally incurable, but improvable with treatment, and often gets progressively worse if not treated properly. Most males with mild or intermediate disease restricted to foreskin or glans can be cured by either medical or surgical treatment.[4]

Signs and symptoms

LS can occur without symptoms. White patches on the LS body area, itching, pain, dyspareunia (in genital LS), easier bruising, cracking, tearing and peeling, and hyperkeratosis are common symptoms in both men and women. In women, the condition most commonly occurs on the vulva and around the anus with ivory-white elevations that may be flat and glistening.

In males, the disease may take the form of whitish patches on the foreskin and its narrowing (preputial stenosis), forming an "indurated ring", which can make retraction more difficult or impossible (phimosis). In addition there can be lesions, white patches or reddening on the glans. In contrast to women, anal involvement is less frequent. Meatal stenosis, making it more difficult or even impossible to urinate, may also occur.

On the non-genital skin, the disease may manifest as porcelain-white spots with small visible plugs inside the orifices of hair follicles or sweat glands on the surface. Thinning of the skin may also occur.[5]

Psychological effect

Distress due to the discomfort and pain of lichen sclerosus is normal, as are concerns with self-esteem and sex. Counseling can help.

According to the National Vulvodynia Association, which also supports women with lichen sclerosus, vulvo-vaginal conditions can cause feelings of isolation, hopelessness, low self-image, and much more. Some women are unable to continue working or have sexual relations and may be limited in other physical activities.[6] [7] Depression, anxiety, and even anger are all normal responses to the ongoing pain LS patients experience.

Pathophysiology

Although it is not clear what causes LS, several theories have been postulated. Lichen sclerosus is not contagious; it cannot be caught from another person.[8]

Several risk factors have been proposed, including autoimmune diseases, infections and genetic predisposition.[9] [10] There is evidence that LS can be associated with thyroid disease.[11]

Genetic

Lichen sclerosus may have a genetic component. A high correlation of lichen sclerosus has been reported between twins[12] [13] and between family members.[14]

Autoimmunity

Autoimmunity is a process in which the body fails to recognize itself and therefore attacks its own cells and tissue. Specific antibodies have been found in LS. Furthermore, there seems to be a higher prevalence of other autoimmune diseases such as diabetes mellitus type 1, vitiligo, alopecia areata, and thyroid disease.[15] [16]

Infection

Both bacterial as well as viral pathogens have been implicated in the etiology of LS. A disease that is similar to LS, acrodermatitis chronica atrophicans is caused by the spirochete Borrelia burgdorferi. Viral involvement of HPV[17] and hepatitis C[18] are also suspected.

A link with Lyme disease is shown by the presence of Borrelia burgdorferi in LSA biopsy tissue.[19]

Hormones

Since LS in females is primarily found in women with a low estrogen state (prepubertal and postmenopausal women), hormonal influences were postulated. To date though, very little evidence has been found to support this theory.

Local skin changes

Some findings suggest that LS can be initiated through scarring[20] or radiation,[21] [22] although these findings were sporadic and very uncommon.

Diagnosis

The disease often goes undiagnosed for several years, as it is sometimes not recognized and misdiagnosed as thrush or other problems and not correctly diagnosed until the patient is referred to a specialist when the problem does not clear up.

A biopsy of the affected skin can be done to confirm diagnosis. When a biopsy is done, hyperkeratosis, atrophic epidermis, sclerosis of dermis and lymphocyte activity in dermis are histological findings associated with LS. The biopsies are also checked for signs of dysplasia.[23]

It has been noted that clinical diagnosis of BXO can be "almost unmistakable," though there are other dermatologic conditions such as lichen planus, localized scleroderma, leukoplakia, vitiligo, and the cutaneous rash of Lyme disease can have a similar appearance.[24]

Treatment

Main treatment

There is no definitive cure for LS.[25] Behavior change is part of treatment. The patient should minimize or preferably stop scratching LS-affected skin.[26] Any scratching, stress or damage to the skin can worsen the disease. Scratching has been theorized to increase cancer risks.[27] Furthermore, the patient should wear comfortable clothes and avoid tight clothing, as it is a major factor in the severity of symptoms in some cases.[28]

Topically applied corticosteroids to the LS-affected skin are the first-line treatment for lichen sclerosus in women and men, with strong evidence showing that they are "safe and effective" when appropriately applied, even over long courses of treatment, rarely causing serious adverse effects.[29] [30] [31] [32] [33] They improve or suppress all symptoms for some time, which highly varies across patients, until it is required to use them again.[34] Methylprednisolone aceponate has been used as a safe and effective corticosteroid for mild and moderate cases. For severe cases, it has been theorized that mometasone furoate might be safer and more effective than clobetasol. Recent studies have shown that topical calcineurin inhibitors such as tacrolimus can have an effect similar to corticosteroids, but its effects on cancer risks in LS are not conclusively known.[35] [36] Based on limited evidence, a 2011 Cochrane review concluded that clobetasol propionate, mometasone furoate, and pimecrolimus (calcineurin inhibitor) all are effective therapies in treating genital lichen sclerosus.[37] However, randomized-controlled trials are needed to further identify the optimal potency and regimen of topical corticosteroids and assess the duration of remission and/or the prevention of flares patients experience with these topical therapies.

Continuous usage of appropriate doses of topical corticosteroids is required to ensure symptoms stay relieved over the patient's life time. If continuously used, corticosteroids have been suggested to minimize the risk of cancer in various studies. In a prospective longitudinal cohort study of 507 women throughout 6 years, cancer occurred for 4.7% of patients who were only "partially compliant" with corticosteroid treatment, while it occurred in 0% of cases where they were "fully compliant".[38] In a second study, of 129 patients, cancer occurred in 11% of patients, none of which were fully compliant with corticosteroid treatment.[39] Both these studies however also said that a corticosteroid as powerful as clobetasol is not necessary in most cases. In a prospective study of 83 patients, throughout 20 years, 8 patients developed cancer. 6 already had cancer at presentation and had not had treatment, while the other 2 were not taking corticosteroids often enough. In all three studies, every single cancer case observed occurred in patients who were not taking corticosteroids as often as the study recommended.

Continuous, abundant usage of emollients topically applied to the LS-affected skin is recommended to improve symptoms. They can supplement but not replace corticosteroid therapy.[30] [40] They can be used much more frequently than corticosteroids due to the extreme rarity of serious adverse effects. Appropriate lubrication should be used every time before and during sex in genital LS in order to avoid pain and worsening the disease.[41] Some oils such as olive oil and coconut oil can be used to accomplish both the emollient and sexual lubrication function.

In males, it has been reported that circumcision can have positive effects, but does not necessarily prevent further flares of the disease[42] and does not protect against the possibility of cancer.[43] Circumcision does not prevent or cure LS; in fact, "balanitis xerotica obliterans" in men was first reported as a condition affecting a set of circumcised men, by Stühmer in 1928.

Other treatments

Carbon dioxide laser treatment is safe and effective, and it improves symptoms over a long time,[44] but it does not lower cancer risks.

Platelet-rich plasma was reported to be effective in one study, producing large improvements in the patients' quality of life, with an average IGA improvement of 2.04 and DLQI improvement of 7.73.[45]

Prognosis

The disease can last for a considerably long time. Occasionally, "spontaneous cure" may ensue,[46] particularly in young girls.

Lichen sclerosus is associated with a higher risk of cancer.[47] [48] [49] [50] Skin that has been scarred as a result of lichen sclerosus is more likely to develop skin cancer. Women with lichen sclerosus may develop vulvar carcinoma.[51] [52] Lichen sclerosus is associated with 3–7% of all cases of vulvar squamous cell carcinoma.[53] In women, it has been reported that 33.6 times higher vulvar cancer risk is associated with LS.[54] [55] A study in men reported that "The reported incidence of penile carcinoma in patients with BXO is 2.6–5.8%".[56]

Epidemiology

There is a bimodal age distribution in the incidence of LS in women. It occurs in females with an average age of diagnosis of 7.6 years in girls and 60 years old in women. The average age of diagnosis in boys is 9–11 years old.[57]

In men, the most common age of incidence is 21–30.[58]

History

In 1875, Weir reported what was possible vulvar or oral LS as "ichthyosis." In 1885, Breisky described kraurosis vulvae. In 1887, Hallopeau described a series of extragenital cases of LS. In 1892, Darier formally described the classic histopathology of LS. In 1900 the concept was formed that scleroderma and LS are closely related, which continues to this day. In 1901, pediatric LS was described. From 1913 to present, the concept that scleroderma is not closely related to LS also was formed. In 1920, Taussig established vulvectomy as the treatment of choice for kraurosis vulvae, a premalignant condition. In 1927, Kyrle defined LS ("white spot disease") as an entity sui generis. In 1928, Stühmer described balanitis xerotica obliterans as a postcircumcision phenomenon. In 1936, retinoids (vitamin A) were used in LS. In 1945, testosterone was used in genital LS. In 1961, the use of corticosteroids started. Jeffcoate presented an argument against vulvectomy for simple LS. In 1971, progesterone was used in LS. Wallace defined clinical factors and the epidemiology of LS. In 1976, Friedrich defined LS as a dystrophic, not an atrophic condition; "et atrophicus" was dropped. The International Society for Study of Vulvar Disease classification system established that "kraurosis" and "leukoplakia" were no longer to be used. In 1980, fluorinated and superpotent steroids were first used in LS. In 1981, studies into HLA serotypes and LS were published. In 1984, etretinate and acetretin were used in LS. In 1987, LS was linked with Borrelia infection.

Lichen sclerosus et atrophicus was first described in 1887 by François Henri Hallopeau.[59] Since not all cases of lichen sclerosus exhibit atrophic tissue, et atrophicus was dropped in 1976 by the International Society for the Study of Vulvovaginal Disease (ISSVD), officially proclaiming the name lichen sclerosus.[60]

See also

External links

Medical pictures

Notes and References

  1. Book: James, William D. . Andrews' Diseases of the Skin: clinical Dermatology . Saunders Elsevier . 2006 . 227 . 0-7216-2921-0 . Berger . Timothy G. .
  2. Web site: Lichen sclerosus . 14 June 2022 . Autoimmune Registry Inc..
  3. Meffert . Jeffrey J . Davis . Brian M . Grimwood . Ronald E . Lichen sclerosus . Journal of the American Academy of Dermatology . March 1995 . 32 . 3 . 393–416 . 10.1016/0190-9622(95)90060-8. 7868709 .
  4. European Dermatology Forum Guideline on Lichen Sclerosus (2014)
  5. Lichen sclerosus et atrophicus and related disorders . Laymon . CW . 1951 . AMA Archives of Dermatology and Syphilology . 5 . 64 . 620–627 . 14867888 . 10.1001/archderm.1951.01570110090013.
  6. Web site: National Vulvodynia Association. Vulvodynia Fact Sheet. Vulvodynia Media Corner. National Vulvodynia Association. 16 June 2012.
  7. The Female Sexual Function Index to assess patients with moderate to severe vulvar lichen sclerosus . Gutierrez-Ontalvilla . Patricia . 2019 . European Journal of Dermatology . 4 . 29 . 430–431 . 31625922 . 10.1684/ejd.2019.3580. 204775452 .
  8. Web site: Fast Facts About Lichen Sclerosus. National Institute of Health. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Lichen Sclerosus. 16 June 2012. 15 June 2012. https://web.archive.org/web/20120615214724/http://www.niams.nih.gov/health_info/Lichen_Sclerosus/default.asp. dead.
  9. Lichen sclerosus . Yesudian . PD . Sugunendran, H . Bates, CM . O'Mahony, C . 2005 . International Journal of STD & AIDS. 7 . 16 . 465–473 . 16004624 . 10.1258/0956462054308440. 21471620 .
  10. 10.1016/j.ejcb.2004.12.003 . Immune dysregulation in lichen sclerosus . Regauer . S . 2005 . European Journal of Cell Biology. 2–3 . 84 . 273–277 . 15819407.
  11. High prevalence of thyroid disease in patients with lichen sclerosus . Birenbaum . DL . Young, RC . 2007 . The Journal of Reproductive Medicine. 1 . 52 . 28–30 . 17286064.
  12. Meyrick Thomas. RH. Kennedy, CT . The development of lichen sclerosus et atrophicus in monozygotic twin girls.. The British Journal of Dermatology. Mar 1986. 114. 3. 377–379. 3954957. 10.1111/j.1365-2133.1986.tb02831.x. 11142666.
  13. Cox. NH. Mitchell, JN . Morley, WN . Lichen sclerosus et atrophicus in non-identical female twins.. The British Journal of Dermatology. Dec 1986. 115. 6. 743–746. 3801314. 10.1111/j.1365-2133.1986.tb06659.x. 40455781.
  14. Sherman. V. McPherson, T . Baldo, M . Salim, A . Gao, XH . Wojnarowska, F . The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study.. Journal of the European Academy of Dermatology and Venereology. Sep 2010. 24. 9. 1031–1034. 20202060. 10.1111/j.1468-3083.2010.03572.x. 1358288.
  15. Lichen sclerosus et atrophicus and autoimmunity—a study of 350 women . Meyrick Thomas . RH . Ridley, CM . McGibbon, DH . Black, MM. 1988 . British Journal of Dermatology. 1 . 118 . 41–46 . 3342175. 10.1111/j.1365-2133.1988.tb01748.x . 37200022 .
  16. Fruchter. R.. Melnick. L.. Pomeranz. M.K.. 2017-03-27. Lichenoid vulvar disease: A review. International Journal of Women's Dermatology. 3. 1. 58–64. 10.1016/j.ijwd.2017.02.017. 2352-6475. 5419035. 28492056.
  17. 10.1046/j.1525-1470.1998.1998015085.x . Human papillomavirus is present in some cases of childhood penile lichen sclerosus: an in situ hybridization and SP-PCR study . Drut. RM . Gomez, MA . Drut, R . Lojo, MM . 1998 . Pediatric Dermatology. 2 . 15 . 85–90 . 9572688. 10110510 .
  18. 10.1111/j.1365-2133.2004.05707.x . Lichen sclerosus-lichen planus overlap in a patient with hepatitis C virus infection . Yashar. S . Han, KF . Haley, JC . 2004 . British Journal of Dermatology. 1 . 150 . 168–169 . 14746647. 9261207 .
  19. Possible Role of Borrelia burgdorferi Sensu Lato Infection in Lichen Sclerosus . Eisendle. K . Grabner, TG . Kutzner, H . 2008 . Archives of Dermatology. 5 . 144. 591–598. 18490585 . 10.1001/archderm.144.5.591.
  20. An unusual variant of lichen sclerosus et atrophicus: delayed appearance in a surgical scar . Pass. CJ . 1984 . Cutis . 4 . 33 . 405 . 6723373.
  21. Lichen sclerosus et atrophicus following sunburn . Milligan. A . Graham-Brown, RA . Burns, DA. 1988 . Clinical and Experimental Dermatology. 1 . 13 . 36–37 . 3208439.
  22. 10.1001/archderm.121.8.1044 . Lichen sclerosus et atrophicus following radiation therapy . Yates. VM . King, CM . Dave, VK. 1985 . Archives of Dermatology. 8 . 121 . 1044–1047 . 4026344.
  23. Shelley . W. B. . Shelley . E. D. . Amurao . C. V. . 10.1111/j.1365-4632.2006.02978.x . Treatment of lichen sclerosus with antibiotics . International Journal of Dermatology . 45 . 9 . 1104–1106 . 2006 . 16961523. 27778016 .
  24. Depasquale. I.. Park. A.J.. Bracka. A.. The treatment of balanitis xerotica obliterans. BJU International. 86. 4. 2000. 459–465. 1464-4096. 10.1046/j.1464-410X.2000.00772.x. 10971272. 32219826.
  25. Chi. CC. Kirtschig, G . Baldo, M . Lewis, F . Wang, SH . Wojnarowska, F . Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus.. Journal of the American Academy of Dermatology. Aug 2012. 67. 2. 305–12. 22483994. 10.1016/j.jaad.2012.02.044.
  26. ACOG Practice Bulletin No. 93: Diagnosis and Management of Vulvar Skin Disorders. 18448767 . 10.1097/AOG.0b013e31817578ba . 111. 5. May 2008. Obstetrics & Gynecology. 1243–53. free.
  27. Does lichen sclerosus play a central role in the pathogenesis of human papillomavirus negative vulvar squamous cell carcinoma? The itch-scratch-lichen sclerosus hypothesis . International Journal of Gynecological Cancer . March 1999 . 9 . 2 . 89–97 . 10.1046/j.1525-1438.1999.99016.x. Scurry . 11240748 .
  28. Todd. P.. Halpern. S.. Kirby. J.. Pembroke. A.. Lichen sclerosus and the Kobner phenomenon. Clinical and Experimental Dermatology. 19. 3. 1994. 262–263. 0307-6938. 10.1111/j.1365-2230.1994.tb01183.x. 8033394. 29331610. free.
  29. Dalziel. K.L.. Millard. P.R.. Wojnarowska. F.. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol Propionate 0.05%) cream. British Journal of Dermatology. 124. 5. 1991. 461–464. 0007-0963. 10.1111/j.1365-2133.1991.tb00626.x. 2039723. 44975544.
  30. Garzon. Maria C.. Paller. Amy S.. Ultrapotent Topical Corticosteroid Treatment of Childhood Genital Lichen Sclerosus. Archives of Dermatology. 135. 5. 525–8. 1999. 0003-987X. 10.1001/archderm.135.5.525. 10328191.
  31. Dahlman-Ghozlan. Kristina. Hedblad. Mari-Anne. von Krogh. Geo. Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: A retrospective clinical and histopathologic study. Journal of the American Academy of Dermatology. 40. 3. 1999. 451–457. 0190-9622. 10.1016/S0190-9622(99)70496-2. 10071317.
  32. Neill. S.M.. Lewis. F.M.. Tatnall. F.M.. Cox. N.H.. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. British Journal of Dermatology. 163. 4. 2010. 672–682. 0007-0963. 10.1111/j.1365-2133.2010.09997.x. 20854400. 16634027. free.
  33. Neill. S.M.. Tatnall. F.M.. Cox. N.H.. Guidelines for the management of lichen sclerosus. British Journal of Dermatology. 147. 4. 2002. 640–649. 0007-0963. 10.1046/j.1365-2133.2002.05012.x. 12366407. 31834145.
  34. Renaud-Vilmer. Catherine. Cavelier-Balloy. Bénédicte. Porcher. Raphaël. Dubertret. Louis. Vulvar Lichen Sclerosus. Archives of Dermatology. 140. 6. 2004. 709–712. 0003-987X. 10.1001/archderm.140.6.709. 15210462.
  35. Li. Y. Xiao, Y . Wang, H . Li, H . Luo, X . Low-concentration topical tacrolimus for the treatment of anogenital lichen sclerosus in childhood: maintenance treatment to reduce recurrence.. Journal of Pediatric and Adolescent Gynecology. Aug 2013. 26. 4. 239–42. 24049806. 10.1016/j.jpag.2012.11.010.
  36. Maassen. MS. van Doorn, HC. [Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors].. Nederlands Tijdschrift voor Geneeskunde. 2012. 156. 36. A3908. 22951124.
  37. Chi. Ching-Chi. Kirtschig. Gudula. Baldo. Maha. Brackenbury. Fabia. Lewis. Fiona. Wojnarowska. Fenella. 2011-12-07. Topical interventions for genital lichen sclerosus. The Cochrane Database of Systematic Reviews. 2011 . 12. CD008240. 10.1002/14651858.CD008240.pub2. 1469-493X. 22161424. 7025763.
  38. Lee. Andrew. Bradford. Jennifer. Fischer. Gayle. Long-term Management of Adult Vulvar Lichen Sclerosus. JAMA Dermatology. 151. 10. 2015. 1061–7. 2168-6068. 10.1001/jamadermatol.2015.0643. 26070005. free.
  39. Bradford. J.. Fischer. G.. Long-term management of vulval lichen sclerosus in adult women. Australian and New Zealand Journal of Obstetrics and Gynaecology. 50. 2. 2010. 148–152. 0004-8666. 10.1111/j.1479-828X.2010.01142.x. 20522071. 43273940.
  40. Fistarol. Susanna K.. Itin. Peter H.. Diagnosis and Treatment of Lichen Sclerosus. American Journal of Clinical Dermatology. 14. 1. 2012. 27–47. 1175-0561. 10.1007/s40257-012-0006-4. 23329078. 3691475.
  41. Smith. Yolanda R. Haefner. Hope K. Vulvar Lichen Sclerosus. American Journal of Clinical Dermatology. 5. 2. 2004. 105–125. 1175-0561. 10.2165/00128071-200405020-00005. 15109275. 22448081.
  42. Lewis . F.M. . Tatnall . F.M. . Velangi . S.S. . Bunker . C.B. . Kumar . A. . Brackenbury . F. . Mohd Mustapa . M.F. . Exton . L.S. . McHenry . P.M. . Leslie . T.A. . Wakelin . S. . Hunasehally . R.Y.P. . Cork . M. . Johnston . G.A. . Chiang . N. . Worsnop . F.S. . Buckley . D. . Petrof . G. . Salin . A. . Callachand . N. . Saunders . C. . Salad . A.A. . British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018 . British Journal of Dermatology . April 2018 . 178 . 4 . 839–853 . 10.1111/bjd.16241. 29313888 . 3416734 . free .
  43. Powell. J.. Robson. A.. Cranston. D.. Wojnarowska. F.. Turner. R.. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. British Journal of Dermatology. 145. 1. 2001. 85–89. 0007-0963. 10.1046/j.1365-2133.2001.04287.x. 11453912. 24738069.
  44. Windahl. T.. Is carbon dioxide laser treatment of lichen sclerosus effective in the long run?. Scandinavian Journal of Urology and Nephrology. 40. 3. 2009. 208–211. 0036-5599. 10.1080/00365590600589666. 16809261. 36979154.
  45. Casabona. Francesco. Gambelli. Ilaria. Casabona. Federica. Santi. Pierluigi. Santori. Gregorio. Baldelli. Ilaria. Autologous platelet-rich plasma (PRP) in chronic penile lichen sclerosus: the impact on tissue repair and patient quality of life. International Urology and Nephrology. 49. 4. 2017. 573–580. 0301-1623. 10.1007/s11255-017-1523-0. 28161837. 11499796.
  46. Smith SD, Fischer G . 2009 . Childhood onset vulvar lichen sclerosus does not resolve at puberty: a prospective case series . Pediatric Dermatology. 26 . 6. 725–9 . 10.1111/j.1525-1470.2009.01022.x. 20199450 . 205677253 .
  47. 10.1016/S0190-9622(99)70245-8 . Penile cancer among patients with genital lichen sclerosus . Nasca. MR . Innocenzi, D . Micali, G. 1999 . Journal of the American Academy of Dermatology. 6 . 41 . 911–914 . 10570372.
  48. Small vulvar squamous cell carcinomas and adjacent tissues. A morphologic study . Poulsen. H . Junge, J . Vyberg, M . Horn, T . Lundvall, F . 2003 . APMIS . 9 . 111 . 835–842 . 14510640 . 10.1034/j.1600-0463.2003.1110901.x. 23716949.
  49. Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey . Barbagli. G . Palminteri, E . Mirri, F . Guazzoni, G . Turini, D . Lazzeri, M . 2006 . Journal of Urology. 4 . 175 . 1359–1363 . 16515998 . 10.1016/S0022-5347(05)00735-4.
  50. Gulin . Sandra Jerkovic . Lundin . Filippa . Seifert . Oliver . 2023-09-11 . Comorbidity in patients with Lichen sclerosus: a retrospective cohort study . European Journal of Medical Research . 28 . 1 . 338 . 10.1186/s40001-023-01335-9 . 2047-783X . 10494448 . 37697418 . free .
  51. Rotondo JC, Borghi A, Selvatici R, Mazzoni E, Bononi I, Corazza M, Kussini J, Montinari E, Gafà R, Tognon M, Martini F . Association of Retinoic Acid Receptor β Gene With Onset and Progression of Lichen Sclerosus-Associated Vulvar Squamous Cell Carcinoma . JAMA Dermatology . 154. 7. 819–823 . 2018 . 29898214. 6128494 . 10.1001/jamadermatol.2018.1373 .
  52. Review of squamous premalignant vulvar lesions . van de Nieuwenhof . HP . van der Avoort . IA. de Hullu. JA . 2008 . Critical Reviews in Oncology/Hematology. 2 . 68 . 131–156 . 18406622 . 10.1016/j.critrevonc.2008.02.012.
  53. Henquet. CJ. Anogenital malignancies and pre-malignancies.. Journal of the European Academy of Dermatology and Venereology. Aug 2011. 25. 8. 885–95. 21272092. 10.1111/j.1468-3083.2010.03969.x. 24203150.
  54. Rotondo JC, Borghi A, Selvatici R, Magri E, Bianchini E, Montinari E, Corazza M, Virgili A, Tognon M, Martini F . Hypermethylation-Induced Inactivation of the IRF6 Gene as a Possible Early Event in Progression of Vulvar Squamous Cell Carcinoma Associated With Lichen Sclerosus . JAMA Dermatology . 152. 8 . 928–33 . 2016 . 27223861 . 10.1001/jamadermatol.2016.1336 .
  55. Halonen. Pia. Jakobsson. Maija. Heikinheimo. Oskari. Riska. Annika. Gissler. Mika. Pukkala. Eero. Lichen sclerosus and risk of cancer. International Journal of Cancer. 140. 9. 2017. 1998–2002. 0020-7136. 10.1002/ijc.30621. 28124469. free.
  56. Pietrzak. Peter. Hadway. Paul. Corbishley. Cathy M.. Watkin. Nicholas A.. Is the association between balanitis xerotica obliterans and penile carcinoma underestimated?. BJU International. 98. 1. 2006. 74–76. 1464-4096. 10.1111/j.1464-410X.2006.06213.x. 16831147.
  57. Fistarol. Susanna K. Diagnosis and treatment of lichen sclerosus: an update.. Journal of the American Academy of Dermatology. 2013. 14 . 1 . 27–47. 10.1007/s40257-012-0006-4. 23329078. 3691475.
  58. Kizer . William S. . Prarie . Troy . Morey . Allen F. . Balanitis Xerotica Obliterans: Epidemiologic Distribution in an Equal Access Health Care System . Southern Medical Journal . January 2003 . 96 . 1 . 9–11 . 10.1097/00007611-200301000-00004. 12602705 . 45454913 .
  59. Du lichen plan et particulièrement de sa forme atrophique: lichen plan scléreux . Hallopeau . H . 1887 . Annales de Dermatologie et de Syphiligraphie . 8 . 790–791 .
  60. Lichen sclerosus . Friedrich Jr. . EG . 1976 . The Journal of Reproductive Medicine. 3 . 17 . 147–154 . 135083.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lichen sclerosus".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.